Elevance Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for Elevance Health (ELV).

Price Target Range — 8 Quarters

Analyst Consensus — 20 Analysts

14Buy

6Hold

Consensus RatingBuy# Analysts20Avg. Consensus PT$450Upside to Avg. PT+7.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 27, 2026	Wells Fargo	Stephen Baxter	PT Raise	Overweight	$473→$492
Oct 23, 2026	TD Cowen	Ryan Langston	PT Raise	Buy	$465→$495
Oct 22, 2026	UBS	A.J. Rice	PT Raise	Buy	$460→$523
Oct 22, 2026	Guggenheim	Jason Cassorla	PT Raise	Buy	$460→$485
Oct 22, 2026	Morgan Stanley	Erin Wright	PT Raise	Equal-Weight	$404→$449
Oct 22, 2026	RBC Capital	Ben Hendrix	PT Raise	Sector Perform	$424→$455
Oct 22, 2026	Barclays	Andrew Mok	PT Raise	Overweight	$469→$472
Oct 22, 2026	Baird	Michael Ha	PT Raise	Neutral	$393→$406
Oct 12, 2026	Guggenheim	Jason Cassorla	PT Raise	Buy	$455→$460
Oct 7, 2026	Barclays	Andrew Mok	PT Raise	Overweight	$457→$469
Jul 17, 2026	Bernstein	Lance Wilkes	PT Raise	Outperform	$482→$488
Jul 17, 2026	Leerink Partners	Whit Mayo	PT Raise	Market Perform	$364→$395
Jul 16, 2026	RBC Capital	Ben Hendrix	PT Cut	Sector Perform	$439→$424
Jul 16, 2026	Wells Fargo	Stephen Baxter	PT Cut	Overweight	$492→$473
Jul 16, 2026	Guggenheim	Jason Cassorla	PT Raise	Buy	$399→$455
Jul 16, 2026	Barclays	Andrew Mok	PT Cut	Overweight	$480→$457
Jul 16, 2026	Baird	Michael Ha	PT Raise	Neutral	$331→$393
Jul 14, 2026	TD Cowen	Ryan Langston	PT Raise	Buy	$400→$465
Jul 14, 2026	Truist Securities	David Macdonald	PT Raise	Buy	$450→$475
Jul 13, 2026	Wells Fargo	Stephen Baxter	PT Raise	Overweight	$391→$492

Analyst Ratings News

PRO
Wells Fargo Maintains Overweight on Elevance Health, Raises Price Target to $492

Wells Fargo analyst Stephen Baxter maintains Elevance Health (NYSE:ELV) with a Overweight and raises the price target from $473 to $492.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Elevance Health, Raises Price Target to $495

TD Cowen analyst Ryan Langston maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $465 to $495.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Elevance Health, Raises Price Target to $523

UBS analyst A.J. Rice maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $460 to $523.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $485

Guggenheim analyst Jason Cassorla maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $460 to $485.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Elevance Health, Raises Price Target to $449

Morgan Stanley analyst Erin Wright maintains Elevance Health (NYSE:ELV) with a Equal-Weight and raises the price target from $404 to $449.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Elevance Health, Raises Price Target to $455

RBC Capital analyst Ben Hendrix maintains Elevance Health (NYSE:ELV) with a Sector Perform and raises the price target from $424 to $455.

Benzinga Newsdesk

Elevance Health Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Elevance Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Wells Fargo Maintains Overweight on Elevance Health, Raises Price Target to $492

PRO
TD Cowen Maintains Buy on Elevance Health, Raises Price Target to $495

PRO
UBS Maintains Buy on Elevance Health, Raises Price Target to $523

PRO
Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $485

PRO
Morgan Stanley Maintains Equal-Weight on Elevance Health, Raises Price Target to $449

PRO
RBC Capital Maintains Sector Perform on Elevance Health, Raises Price Target to $455

People Also Watch

People Also Watch

Elevance Health Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Elevance Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWells Fargo Maintains Overweight on Elevance Health, Raises Price Target to $492

PROTD Cowen Maintains Buy on Elevance Health, Raises Price Target to $495

PROUBS Maintains Buy on Elevance Health, Raises Price Target to $523

PROGuggenheim Maintains Buy on Elevance Health, Raises Price Target to $485

PROMorgan Stanley Maintains Equal-Weight on Elevance Health, Raises Price Target to $449

PRORBC Capital Maintains Sector Perform on Elevance Health, Raises Price Target to $455

People Also Watch

People Also Watch

PRO
Wells Fargo Maintains Overweight on Elevance Health, Raises Price Target to $492

PRO
TD Cowen Maintains Buy on Elevance Health, Raises Price Target to $495

PRO
UBS Maintains Buy on Elevance Health, Raises Price Target to $523

PRO
Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $485

PRO
Morgan Stanley Maintains Equal-Weight on Elevance Health, Raises Price Target to $449

PRO
RBC Capital Maintains Sector Perform on Elevance Health, Raises Price Target to $455